Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SPRC | US
0.06
26.53%
Healthcare
Biotechnology
31/03/2024
21/10/2024
0.29
0.23
0.30
0.23
SciSparc Ltd. a specialty clinical-stage pharmaceutical company develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome obstructive sleep apnea and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety tolerability and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. SciSparc Ltd. has collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. The company was incorporated in 2004 and is headquartered in Tel Aviv-Yafo Israel.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
134.5%1 month
107.0%3 months
118.2%6 months
97.9%-
-
0.31
0.01
0.01
1.21
0.05
-
-5.28M
3.00M
3.00M
-
-309.37
-
-32.70
-73.37
0.51
8.03
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.09
Range1M
0.09
Range3M
0.49
Rel. volume
4.74
Price X volume
1.51M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
22nd Century Group Inc | XXII | Biotechnology | 0.105 | 3.30M | 0.10% | n/a | -1072.15% |
Aptevo Therapeutics Inc | APVO | Biotechnology | 0.2389 | 3.21M | 20.35% | n/a | 112.59% |
Galera Therapeutics Inc | GRTX | Biotechnology | 0.0555 | 3.07M | 2.78% | n/a | -0.87% |
NovaBay Pharmaceuticals Inc | NBY | Biotechnology | 0.6211 | 3.03M | -1.38% | n/a | -325.77% |
Hiru Corporation | HIRU | Biotechnology | 0.0016 | 3.02M | -15.79% | n/a | 263.27% |
Ensysce Biosciences Inc | ENSC | Biotechnology | 0.206 | 2.86M | 15.86% | n/a | 24.79% |
Cyclacel Pharmaceuticals Inc | CYCC | Biotechnology | 1.32 | 2.84M | 15.79% | n/a | 0.50% |
Phio Pharmaceuticals Corp | PHIO | Biotechnology | 3.18 | 2.74M | 9.28% | n/a | 0.00% |
Salarius Pharmaceuticals Inc | SLRX | Biotechnology | 1.82 | 2.62M | -9.45% | n/a | 0.00% |
ZVSA | ZVSA | Biotechnology | 2.3 | 2.47M | 0.00% | 0.00 | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 1.21 | 0.53 | Expensive |
Ent. to Revenue | 0.05 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 0.31 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 118.23 | 72.80 | Riskier |
Debt to Equity | 0.01 | -1.23 | Expensive |
Debt to Assets | 0.01 | 0.25 | Cheaper |
Market Cap | 3.00M | 3.66B | Emerging |